18September2018

A Newspaper for the health conscious

AVONIC LIFE SCIENCES

Pinorc Life Science


Dr S Eswara Reddy
1 1 1 1 1 1 1 1 1 1 Rating 5.00 (1 Vote)

Central panel to decide compensation in faulty ASR hip implants

Rohit Shishodia
Central government has formed a central expert panel to determine the quantum of compensation for the affected patients of faulty ASR hip implants.

1 1 1 1 1 1 1 1 1 1 Rating 5.00 (2 Votes)

Faulty hip implants: Panel recommends J&J should reimburse patients

Rohit Shishodia
An eleven member expert panel has recommended to the government for extension of reimbursement program for patients who have undergone ASR (acetabular surface replacement) hip implants and suffered from adverse affects due to the faulty implants.

Gagan Singh, MD, AstraZeneca Pharma India
1 1 1 1 1 1 1 1 1 1 Rating 5.00 (1 Vote)

AstraZeneca gets DCGI nod to sell cancer drug in India

BS RAWAT

NEW DELHI: AstraZeneca Pharma India has said that it has received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets used for the treatment of ovarian and breast cancer.

1 1 1 1 1 1 1 1 1 1 Rating 5.00 (1 Vote)

Indian insurance industry to be US$ 280bn by 2020

BS RAWAT
NEW DELHI: The Indian insurance industry is expected to grow to US$ 280 billion by FY 2020 with the center’s Ayushman Bharat and other growth drivers like rising disposable incomes, presence of global players and easing of the regulatory regime, helping penetration of the insurance culture in the country, according to an ASSOCHAM-APAS study.

Mr Rajiv Nath
1 1 1 1 1 1 1 1 1 1 Rating 5.00 (2 Votes)

Hindustan Syringes and Medical Devices gets MDSAP certification

DTMT Network
Hindustan Syringes and Medical Devices and Niraj Industries have become the first set of Indian manufacturers of disposable medical devices to achieve Medical Devices Single Audit Program (MDSAP) quality assurance certificate.

1 1 1 1 1 1 1 1 1 1 Rating 5.00 (1 Vote)

Amid protest, price cap on knee implants extended

BS RAWAT

NEW DELHI: The National Pharmaceutical Pricing Authority (NPPA) has extended the price cap imposed on orthopaedic knee implants by another year till August, 2019.

GLS Pharma

Cubit Pharma